undamentalytics Newsletter
Sign in

Curis Inc (CRIS) stock

Add to watchlist

Add holding +

NASDAQ: CRIS Nasdaq Biotechnology Next results ~November 5, 2026

E Fundamentals grade

Curis Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Curis Inc is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Curis Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds1 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Curis files

Where Curis stands after its latest 10-Q

Curis has little or no product revenue yet; it used $31m of cash in the twelve months to June 2026. That puts it 105 of 122 for growth among the biotechnology companies we cover. The diluted share count is up 39.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 1 of our 2 financial-health checks.

Our model value for Curis is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Curis Inc's trailing-twelve-month revenue fell 62.2% year on year, with a free-cash-flow margin of -709.0%. Where it lags: change in share count of 90.7% ranks 151 of 156 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -62.2% (-25.2pp vs the prior quarter), the 3rd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 129.8 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 62.2% over the last 12 months.
  • Growth slowing. The growth rate is 25.2 points lower than a quarter earlier.
  • Loss-making. Operating margin is -203.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -709.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 66.4% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 90.7% in a year.

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$4.02 against an average estimate of -$5.21: beat by 22.8%
Next report
November 5, 2026; average EPS estimate -$2.01

Curis' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+10.0%
  • 1 week+73.7%
  • 1 month-17.5%
  • This year-96.7%
  • 1 year-97.8%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$4.3M
Operating margin
-203.2%
Net margin
-490.3%
EPS (TTM, diluted)
$-38.04

Growth

Revenue growth
−62.2%
Change in growth rate
−25.2 pts
Share count change
+90.7%

Cash

Free cash flow (TTM)
-$30.6M
FCF margin
-709.0%
Stock pay % of revenue
66.4%

Earnings

Last results
May 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Curis Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Curis Inc as an operating company, with every model that fits that kind of business. Cost of equity 11.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.52 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$17 ~$15–$56 Left out: out of range vs price (26.26x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Curis Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025
Share price$5820.00$6160.00$1400.00$276.00$680.00$3276.00$1904.00$220.00$255.00$61.20$19.80
Market value$28.7bn$32.7bn$8.4bn$1.8bn$4.5bn$31.9bn$17.4bn$2.1bn$2.7bn$772m$261m
+ Net debt (− = net cash)−$9m−$6m$3m$12m−$15m−$129m−$40m−$20m−$18m−$12m−$5m
Enterprise value$28.7bn$32.7bn$8.4bn$1.8bn$4.5bn$31.8bn$17.4bn$2.0bn$2.7bn$759m$256m
Multiples
Price / sales n/mn/mn/m175.3xn/mn/mn/mn/mn/m70.8x27.6x
Price / earnings ———————————
Price / free cash flow ———————————
EV / EBITDA ———————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Curis's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -75.3% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -353.3%; its worst year was -802.5%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -405.1% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 570.8% over five years; stock-based pay has been a median 53.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $0 and EPS of −$2.01 (range −$2.29 to −$1.73) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$23.78 +55% — −100%
Next −$6.01 +75% $9m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −23.8% on 90 days ago. In the last 30 days, 1 analyst raised Curis Inc's forecast and 0 cut it.

Consensus EPS forecast Curis Inc, last 90 days
−$40.00 −$30.00 −$20.00 −$10.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$31.20 Current fiscal year, 60 days ago: −$31.20 Current fiscal year, 30 days ago: −$31.20 Current fiscal year, 7 days ago: −$29.78 Current fiscal year, Now: −$23.78 −$23.78 Next fiscal year, 90 days ago: −$23.73 Next fiscal year, 60 days ago: −$23.73 Next fiscal year, 30 days ago: −$23.73 Next fiscal year, 7 days ago: −$16.23 Next fiscal year, Now: −$6.01 −$6.01

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$31.20−$23.73
60 days ago −$31.20−$23.73
30 days ago −$31.20−$23.73
7 days ago −$29.78−$16.23
Now −$23.78−$6.01

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$5.21 −$4.02 +22.8%
Mar 2026 −$5.80 −$25.00 −331.0%
Dec 2025 −$8.65 −$9.95 −15.0%
Sept 2025 −$12.00 −$9.80 +18.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, May 12, 2026

No numeric guidance in Curis Inc's latest earnings release (filed May 12, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026134
  2. Sep 2026134

Counts of recommendations published by analysts covering Curis Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
18.3%
of tradable shares
Days to cover
2.18
at average volume
Short interest, 1 month
+536%
to October 15, 2026
Held by institutions
17%
of shares
Held by insiders
3.8%
of shares
Employees
20
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CRIS−42%−88%+16%−76%−68%−97%
Industry peers (median)−35%−56%−18%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CRIS33%42%33%42%33%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CRIS−73%−91%−80%−82%−77%−98%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from November 14, 2016 to October 19, 2026. Getting back needed a 1947268% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.38 – $29.60
From 52-week high
−97.8%
vs 50-day average
−26.9%
vs 200-day average
−92.6%
Volatility (1 year)
131%
Beta vs S&P 500
1.72

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±9.8%
After a week
4 up, 8 down
typical move ±20.5%
After a month
4 up, 8 down
typical move ±23.2%
Results releasedNext dayS&P 500 next day5 days21 days
May 12, 2026 −9.1% +0.4% −12.7% −21.8%
March 19, 2026 −6.1% −1.7% −29.3% −24.4%
November 6, 2025 −7.7% −1.0% −20.4% −4.9%
August 5, 2025 +4.4% +0.3% +3.1% +6.9%
May 6, 2025 −15.9% −0.4% −13.5% −2.4%
March 31, 2025 −37.1% +1.0% −50.0% −9.1%
March 28, 2025 −12.9% −1.4% −49.0% −24.9%
November 14, 2024 +0.5% −1.9% +4.3% −11.5%
August 1, 2024 −8.8% −3.3% −17.9% +0.9%
May 7, 2024 +1.1% +0.1% −3.0% −40.2%
February 8, 2024 +10.9% +0.6% +8.8% +10.2%
November 2, 2023 −3.0% +2.8% +33.5% +121.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Curis Inc in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Curis Inc
$4M $6M $8M $10M $12M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $10.2M Revenue (TTM), FY23 Q4: $10M Revenue (TTM), FY24 Q1: $9.8M Revenue (TTM), FY24 Q2: $10.2M Revenue (TTM), FY24 Q3: $10.3M Revenue (TTM), FY24 Q4: $10.9M Revenue (TTM), FY25 Q1: $11.2M Revenue (TTM), FY25 Q2: $11.4M Revenue (TTM), FY25 Q3: $11.7M Revenue (TTM), FY25 Q4: $9.4M Revenue (TTM), FY26 Q1: $7.1M Revenue (TTM), FY26 Q2: $4.3M $4.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $10.2M
FY23 Q4 $10M
FY24 Q1 $9.8M
FY24 Q2 $10.2M
FY24 Q3 $10.3M
FY24 Q4 $10.9M
FY25 Q1 $11.2M
FY25 Q2 $11.4M
FY25 Q3 $11.7M
FY25 Q4 $9.4M
FY26 Q1 $7.1M
FY26 Q2 $4.3M
Revenue growth, TTM YoY Curis Inc
-80% -60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -1.9% Revenue growth, TTM YoY, FY23 Q4: -1.4% Revenue growth, TTM YoY, FY24 Q1: -5.7% Revenue growth, TTM YoY, FY24 Q2: -0.4% Revenue growth, TTM YoY, FY24 Q3: 0.4% Revenue growth, TTM YoY, FY24 Q4: 8.8% Revenue growth, TTM YoY, FY25 Q1: 14.2% Revenue growth, TTM YoY, FY25 Q2: 12.2% Revenue growth, TTM YoY, FY25 Q3: 13.6% Revenue growth, TTM YoY, FY25 Q4: -13.4% Revenue growth, TTM YoY, FY26 Q1: -36.9% Revenue growth, TTM YoY, FY26 Q2: -62.2% -62.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -1.9%
FY23 Q4 -1.4%
FY24 Q1 -5.7%
FY24 Q2 -0.4%
FY24 Q3 0.4%
FY24 Q4 8.8%
FY25 Q1 14.2%
FY25 Q2 12.2%
FY25 Q3 13.6%
FY25 Q4 -13.4%
FY26 Q1 -36.9%
FY26 Q2 -62.2%
Operating margin (TTM) Curis Inc
-600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -453.8% Operating margin (TTM), FY23 Q4: -482.2% Operating margin (TTM), FY24 Q1: -501.2% Operating margin (TTM), FY24 Q2: -487.6% Operating margin (TTM), FY24 Q3: -465.4% Operating margin (TTM), FY24 Q4: -408.3% Operating margin (TTM), FY25 Q1: -377.0% Operating margin (TTM), FY25 Q2: -332.9% Operating margin (TTM), FY25 Q3: -294.6% Operating margin (TTM), FY25 Q4: -60.5% Operating margin (TTM), FY26 Q1: -100.2% Operating margin (TTM), FY26 Q2: -203.2% -203.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -453.8%
FY23 Q4 -482.2%
FY24 Q1 -501.2%
FY24 Q2 -487.6%
FY24 Q3 -465.4%
FY24 Q4 -408.3%
FY25 Q1 -377.0%
FY25 Q2 -332.9%
FY25 Q3 -294.6%
FY25 Q4 -60.5%
FY26 Q1 -100.2%
FY26 Q2 -203.2%
FCF margin (TTM) Curis Inc
-800% -600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -396.7% FCF margin (TTM), FY23 Q4: -383.5% FCF margin (TTM), FY24 Q1: -402.2% FCF margin (TTM), FY24 Q2: -420.6% FCF margin (TTM), FY24 Q3: -394.7% FCF margin (TTM), FY24 Q4: -362.7% FCF margin (TTM), FY25 Q1: -299.8% FCF margin (TTM), FY25 Q2: -267.0% FCF margin (TTM), FY25 Q3: -258.3% FCF margin (TTM), FY25 Q4: -288.1% FCF margin (TTM), FY26 Q1: -409.9% FCF margin (TTM), FY26 Q2: -709.0% -709.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -396.7%
FY23 Q4 -383.5%
FY24 Q1 -402.2%
FY24 Q2 -420.6%
FY24 Q3 -394.7%
FY24 Q4 -362.7%
FY25 Q1 -299.8%
FY25 Q2 -267.0%
FY25 Q3 -258.3%
FY25 Q4 -288.1%
FY26 Q1 -409.9%
FY26 Q2 -709.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 9 16 15 17 15 10 8 8 10 10 10 11 11 10 10 11 9 4
EBITDA −9 −5 −7 −18 −9 −16 −56 −58 −50 −29 −24 −25 −42 −53 −48 −44 −6 −9
Operating income −10 −6 −7 −19 −9 −16 −56 −58 −50 −29 −24 −25 −42 −53 −48 −45 −6 −9
Net income −10 −4 −10 −16 −12 −19 −59 −60 −53 −33 −32 −30 −45 −57 −47 −43 −8 −21
Diluted EPS −$0.04 −$1.50 −$3.25 −$5.25 −$3.75 −$5.50 −$12.00 −$2.25 −$8.95 −$4.90 −$4.85 −$3.05 $5.00 −$6.07 −$4.48 −$3.44 −$0.58 —
Growth (year on year)
Revenue — +86.3% −7.7% +15.0% −11.6% −34.4% −20.0% −4.5% +31.5% +5.4% −4.1% +8.3% −1.7% −4.6% −1.4% +8.8% −13.4% −62.2%
Margins
EBITDA margin −108.2% −30.9% −48.1% −109.0% −61.8% −159.6% −714.9% −768.5% −500.4% −279.6% −242.2% −228.5% −393.5% −519.5% −479.7% −406.5% −58.7% −201.2%
Operating margin −116.9% −35.2% −48.8% −109.7% −62.8% −161.2% −716.9% −771.1% −502.7% −281.3% −243.5% −229.8% −395.0% −521.7% −482.2% −408.3% −60.5% −203.2%
Net margin −114.4% −27.7% −66.8% −96.7% −82.1% −190.3% −748.7% −802.6% −538.7% −312.4% −321.3% −276.0% −426.7% −557.7% −473.0% −397.8% −80.3% −490.3%
Free-cash-flow margin −88.6% −11.9% −32.7% −90.1% −64.6% −171.7% −380.0% −480.1% −490.4% −289.1% −262.4% −243.8% −353.3% −538.8% −383.5% −362.7% −288.1% −709.0%
Cash flow
Cash from operations −8 −2 −5 −15 −10 −17 −30 −36 −48 −30 −26 −26 −38 −54 −38 −40 −27 −31
Capital spending 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
Free cash flow −8 −2 −5 −15 −10 −17 −30 −36 −49 −30 −26 −26 −38 −55 −38 −40 −27 −31
Stock-based pay 2 2 2 4 3 3 4 4 5 4 3 3 5 7 6 6 4 3
Free cash flow after stock pay −9 −4 −7 −19 −13 −20 −34 −40 −54 −34 −29 −29 −43 −62 −44 −45 −31 −33
Balance sheet
Cash 7 8 15 13 10 8 33 26 38 24 15 130 40 20 27 20 5 5
Total debt 0 0 0 30 31 28 24 20 42 36 0 1 0 0 9 8 0 0
Net debt (negative = net cash) −7 −8 −15 17 21 21 −9 −6 3 12 −15 −129 −40 −20 −18 −12 −5 −5
Diluted shares — 3m 3m 3m 3m 3m 5m 5m 6m 7m 7m 10m 9m 9m 11m 13m 13m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 2 checks passed · June 30, 2026
What it owns · $19m
Short-term assets $7mLonger-term assets $12m
What it owes, and who funded it · $19m
Short-term liabilities $14mLonger-term liabilities $1mShareholders' equity $5m
  • Short-term assets cover short-term liabilities $7m of assets due within a year against $14m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $7m short-term assets against $600,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Curis Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+90.7%
year over year
R&D spending
589.2%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated CRIS CAMP ENSC OCGN TRDA BOLT Median
Revenue, last 12 months $4m $4m $5m $5m $5m $5m $56m
Revenue growth, last 12 months −62.2% 40.2% −39.3% −3.7% −94.1% 12.8% 12.6%
Revenue growth, 3-year average −25.0% — 14.6% 26.3% — −11.5% 13.7%
Revenue growth, latest quarter −100.0% 18.8% −15.1% 8.4% −53.9% −99.7% 10.2%
Operating margin −203.2% <−999% −281.3% <−999% <−999% −654.5% −189.4%
Operating margin, 3-year average −341.2% — −347.6% <−999% <−999% −887.4% −363.5%
Net margin −490.3% <−999% −280.5% <−999% <−999% −611.5% −169.8%
Cash from operations / revenue −709.0% −678.2% −196.8% <−999% <−999% −669.2% −168.0%
Free-cash-flow margin −709.0% −681.2% −197.2% <−999% <−999% −669.2% −162.4%
Free-cash-flow margin, 3-year average −465.5% — −165.8% <−999% <−999% −825.2% −310.0%
Stock pay / revenue 66.4% 131.4% 1.8% 201.1% 413.3% 54.1% 20.0%
Change in share count 90.7% — 74.6% 14.1% −0.6% 1.0% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -62.2% 12.6% 149 of 172
Change in growth rate Growth -25.2pp -0.1pp 130 of 172
Operating margin Profitability -203.2% -189.4% 92 of 175
Net margin Profitability -490.3% -157.3% 125 of 180
Free-cash-flow margin Cash generation -709.0% -145.4% 137 of 176
Stock pay as % of revenue Cash generation 66.4% 19.2% 123 of 179
Change in share count Balance sheet 90.7% 7.9% 151 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$8
Institutions reporting
1
Positions opened / closed
1 / 0

Top buyers and sellers, Q2 2026: 1 institutions bought and 0 sold ; the biggest buyer was Sbi Securities Co., Ltd (+15 shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Sbi Securities Co., Ltd. $8 0K 100.0% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Curis Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $5,500 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $5,500 net buying
Insider Date Trade Shares Price Value
Kaitin Kenneth I Director March 31, 2026 Buy 10,000 $0.55 $5,500

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around August 4, 2026 estimated from the company's past filing pattern, not announced

  • May 12, 2026
  • March 19, 2026
  • November 6, 2025
  • August 5, 2025
  • May 6, 2025
  • March 31, 2025

Recent SEC filings

Data status

When each part of this page on Curis Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Curis Inc in brief

What does Curis Inc do?
Curis Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Curis Inc's stock ticker?
Curis Inc trades under the ticker CRIS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Curis Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Curis Inc reported revenue of $4.3M, 62.2% lower than a year earlier, according to its SEC filings.
What is Curis Inc's free cash flow?
Curis Inc's free-cash-flow margin is -709.0% of revenue over the trailing twelve months, ranking 137 of the 176 biotechnology companies we cover.
What is Curis Inc's market cap?
On December 31, 2025, Curis Inc's market capitalisation was about $261M and net debt of -$5.1M. Market figures come from third-party market data and may be delayed.
Who are Curis Inc's competitors?
In our Biotechnology peer group, the companies closest to Curis Inc are Camp4 Therapeutics Corp, Ensysce Biosciences, Inc., Ocugen, Inc., Entrada Therapeutics, Inc. and Bolt Biotherapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Curis Inc's.
Are insiders buying or selling Curis Inc stock?
Over the last 12 months, Curis Inc's directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Curis Inc's next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Curis Inc announces its own schedule.